A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole (MARIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05178862

Recruitment Status : Suspended (During a review of manufacturing equipment and cleaning activities at a supplier that manufactured study drug for this study, SCYNEXIS was made aware of potential cross-contamination risk with a non-antibacterial beta-lactam drug substance.)

First Posted : January 5, 2022

Last Update Posted : November 18, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Scynexis, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Suspended
Estimated Primary Completion Date :	June 2024
Estimated Study Completion Date :	August 2024

To Top